Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: A pilot study

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 9, 1999, Pages 1187-1193

  Fabris, P ^a   Tositti, G ^a   Mazzella, G ^b   Zanetti, A R ^c   Nicolin, R ^a   Pellizzer, G ^a   Benedetti, P ^a   De Lalla, F ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BILE ACID BLOOD LEVEL; BIOCHEMISTRY; CHOLESTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; FEMALE; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS E VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS HEPATITIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHENODEOXYCHOLIC ACID; CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS; CHOLIC ACID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS ANTIBODIES; HEPATITIS VIRUSES; HEPATITIS, VIRAL, HUMAN; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 0032828362     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00592.x     Document Type: Article

References (37)

1. Palmer RH, Bile acids, liver injury, and liver disease. Arch Intern Med 1972; 130: 606-17.
2. Greim H, Trulzsch D, Czygan P, et al. Mechanism of cholestasis. Bile acids in human livers with or without biliary obstruction. Gastroenterology 1972; 63: 846-50.
3. Sholmerich J, Becher MS, Schmidt KH, et al. Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties. Studies on isolated hepatocytes and lipid membrane vesicles. Hepatology 1984; 4: 661-6.
4. Miyai K, Prince VM, Fisher MM. Bile acid metabolism in mammals. Ultrastructural studies on the intrahepatic cholestasis induced by lithocholic and chenodeoxycholic acids in the rat. Lab Invest 1971; 24: 292-302.
5. King JE, Schoenfield LJ, Lithocholic acid, cholestasis, and liver disease. Mayo Clin Proc 1972; 47: 725-30.
6. Fisher RL, Anderson DW, Boyer JL, et al. A prospective morphologic evaluation of hepatic, toxicity of chenodeoxycholic acid in patients with cholelithiasis: the National Cooperative Gallstone Study. Hepatology 1982; 2: 187-201.
7. Okun R, Van Goldstein LI, Gelder GA, et al. National cooperative gallstone study: non primate toxicology of chenodeoxycholic acid. J Toxicol Environ Health 1982; 9: 727-41.
8. Douglas M, Heuman S, Mills A, et al. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. Gastroenterology 1991; 100: 203-11.
9. Armstrong MJ, Carey MC. The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid Chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res 1982; 23: 70-80.
10. Attili AF, Angelico M, Cantafora A, et al. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 2: 1986(19): 57-68197140: 606-17.
11. Guldtuna S, Zimmer G, Imhof M, et al. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993; 104: 1736-44.
12. Marteau P, Chazouilleres O, Myra A, Jian R, Rambaud JC, Poupon R, Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of the endogenous bile acids in man. Hepatology 1990; 5: 1206-9.
13. Calmus Y, Pierre G, Rouger P, Poupon R, Hepatic expression of Class I and Class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 1: 12-15.
14. Crosignani A, Setchell KDR, Invernizzi P, Larghi A, Rodrigues CMP, Podda M. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet 1996; 30(5): 333-53.
15. Poupon R, Poupon RE, Calmus Y, Chrétien Y, Ballet F, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834-6.
16. Leuschner U, Fisher H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of controlled double-blind trial. Gastroenterology 1989; 97: 1268-74.
17. Simko V, Shoukry M, Prego V. Ursodeoxycholic therapy in chronic liver disease: a metanalysis in primary biliary cirrhosis and in chronic hepatitis. Am J Gostroenterol 1994; 3: 392-8.
18. Crosignani A, Battezzati PMDR, Setchell K, et al. Effect of ursodeoxycholic acid on scrum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose response study. Hepatology 1991; 13: 339-44.
19. Takano S, Ito Y, Yokosuka O, et al. A multicentric randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558-64.
20. Attili AF, Rusticali A, Varriale M, Carli L, Repice AM, Callea F. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. J Hepatol 1994; 20: 315-20.
21. Boucher E, Jouanolle H, Patrice A, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C. hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322-7.
22. Baario J, Catiella A, Lobo C, et al. Cholestatic acute hepatitis induced by amoxycillin-clavulanic acid combination. Role of ursodeoxycholic acid in drug-induced cholestasis. Rev Esp Enferm Dig 1998; 90: 523-6.
23. Kadayifci A, Savas MC, Arslan S, Gullu IH. Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B. J Clin Gastroenterol 1997; 24: 125-6.
24. Roda A, Bolelli GF. Production of high liter antibody to bile acids. J Steroid Biochem 1980; 13: 449-54.
25. Rods A, Girotti S, Carica G, Krincka LJ, De Luca M. Luminimetric methods for bile acids. Methods of enzymatic analyses. In: Hans Ulrich Bergmeyer, ed. Methods of Enzymatic Analysis. Weinheim (Federal Republic of Germany): VCH Verlagageselisellschaft mbH. 1985: 204-376.
26. Schlauder GG, Dawson GJ, Mushawar IK, et al. Viraemia in Egyptian children with hepatitis E virus Infection. Lancet 1993; 341: 378.
27. Imberti L, Cariani E, Bettinardi A, Zonaro A, Albertini A, Primi D. An immunoassay for specific amplified HCV sequences. J Virol Meth 1991; 34: 233-43.
28. Burr JA, Nesselroade JR. Statistical Methods in Longitudinal Research: Principles and Structuring Change. CA, USA: Academic Press, 1990.
29. Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid cholestasis: potential mechanism of action and therapeutical application. Hepatology 1998; 28: 1449-53.
30. Peterslund NA. The concentration of serum bile acids during the course of acute hepatitis B. Scand J Gastroenterol 1980; 15: 405-10.
31. Podda M, Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Roda A. Ursodeoxycholic acid, taurine or a combination of the two for chronic hepatitis. Gastroenterology 1990; 98: 1044-50.
32. Kiso S, Kawata S, Imay Y, et al. Efficacy of Ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum γ-glutamyltranspeptidase levels. J Gastroenterol 1996; 31: 75-80.
33. Roda E, Mazzella G, Bazzoli F, et al. Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis. Dig Dis Sci 1989: 34(Suppl. 12): 52-8.
34. Poupon R, Poupon RE, Lebree D, et al. Mechanism for reduced hepatic clearance and elevated plasma levels of bile acids in cirrhosis. A study in patients with an end-to-side portovacal shunt. Gastroenterology 1981; 80: 1438-44.
35. Beuers U, Spengler U, Zwiebel FM, et al. Effect of ursodeoxycholic acid on the kinetics of the major Hydrophobic bile acids in health and in cholestatic liver diseases. Hepatology 1992; 15: 603-8.
36. Mazzella C, Parini P, Bazzoli F, et al. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci 1993; 38: 896-902.
37. Chretien Y, Poupon R, Gherardt MF, et al. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic acid treatment. Gut 1989; 30: 1110-15.